All-Clear, and Other Misreadings

Market regime

The 9/17 session looked like a resolution: the average US stock rose 0.83% on 1,851 advancers against 1,182 decliners, 1,826 names gained more than 3%, and every sector finished green. Do not confuse that with a repaired market. 614 of those gains were concentrated in Technology, Health Care and Industrials, Communication Services was the only sector to fall, and on a 1-month view just 30% of stocks are positive with the average down 3.2%. Breadth has not improved for weeks: 81% of names changed hands more actively in this rally than the preceding selloff, while the share holding the 50-day remains stuck near 34%. A rally that wide is short-covering into a market that has not yet rebuilt its structure.

Mega forces

1. The term-premium trade. The US 10-year cleared 5% and long-duration Treasuries have lost 5.1% in three months while the dollar gained 1.7%. This is not a growth scare; it is a repricing of government credit. The transmission mechanism is exactly what BlackRock's strategist describes: 20-year yields fading while the S&P sits 2.4% off its high means the discount rate is being repriced at the long end, not in the equity risk premium. Duration-sensitive equities — Utilities (-4.3% over a month), Real Estate (-4.6%), homebuilding (-7.5%) — are being taxed for it.

2. A three-year leadership turnover nobody is pricing as one. Energy leads at +55% over twelve months and Health Care at +72%, while Consumer Discretionary sits at -4% and barely half its names are positive. Over the past three months the average Energy stock is +14.1% and Health Care +15.0% against Industrials -7.8% and Utilities -7.3%. Long-duration, prior-leadership cyclicality is the funding source.

3. Oil is a refining story, not a drilling story. WTI has run 19.9% in a month, but the equity gains are all downstream: refiners and integrated majors sit within 5% of 52-week highs (VLO, MPC, PSX, DINO, DK), while oilfield services lag at -4.6% and pure E&P at +2.0%. Crack spreads, not crude, are paying the shareholders.

What's working

The clearest asymmetry in the data is Health Care breadth against a rising 10-year: 77% of large-cap Health Care is positive over three months, 71% over twelve months, with 22 overbought names against 25 oversold. The re-rating is concentrated in platforms, not therapeutics — Life Science Tools (TXG, CDNA, WGS at 52-week highs, RSI 72-78), Biopharma Discovery (SDGR, MRNA), CROs, and Diagnostics (TEM, CAI). Tools and data price the industry's R&D spend; they carry less binary risk than a Phase 3 and take a mild hit from higher rates.

Energy is a narrower bet but has the best trend quality: 79% of large caps positive over three months, 93% over a year, RSI a healthy 51, 18 overbought against 2 oversold. Marine shipping and oil & gas royalties have joined the move (+7.3% and +5.4%).

Avoid Aerospace & Defense Components: worst theme at -14.7% over a month with only 3.7% of names positive. The July US-Saudi F-35 approval and the Pentagon's production-acceleration agreements reached the order book, not the cash-flow statement — a lesson in theme versus earnings.

Strategy

Use the broad, indiscriminate rally to sell, not buy. Sell the oversold bounce in Financials (43% still below the 50-day, 6-month and 3-month trends inverted), Utilities and Real Estate — those bounces need lower long rates, and the data says the market disagrees. Buy under-owned breadth in Energy and Health Care, with a preference for refining over drilling, and tools over therapeutics. The one mega-cap to avoid is Communication Services, the only sector that failed to rally: it carries platform regulation risk from the youth-access crackdown in Australia and Europe without the earnings floor of an industrial. Finally, respect the event dispersion: a $2.4bn Amazon supply agreement moved GNRC +18%, while LEN missed and the stock fell, in the same week. In this tape the market is paying for company-specific execution — nothing else.